Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

How long should patients with migraine continue to receive prophylactic topiramate?

Nature Clinical Practice Neurology volume 4, pages 294–295 (2008)Cite this article

boxed-textDiener HC et al. (2007) Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 6: 1054–1062

Decisions about migraine prophylaxis with topiramate after 6 months' effective therapy should take into consideration that cessation results in only a small headache-frequency increase, while continuation for another 6 months yields persistent benefit

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Stovner LJ et al. (2007) The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 27: 193–210

    Article  Google Scholar 

  2. Diamond S et al. (2007) Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention Study. Headache 47: 355–363

    PubMed  Google Scholar 

  3. Silberstein SD (2000) Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 55: 754–762

    Article  CAS  Google Scholar 

  4. Fontebasso M (2007) Topiramate for migraine prophylaxis. Expert Opin Pharmacother 8: 2811–2823

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Martina Habeck, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8111, St. Louis, MO 63110, USA schwedtt@neuro.wustl.edu

Authors and Affiliations

  1. TJ Schwedt is Director of the Washington University Headache Center and Assistant Professor of Neurology at Washington University School of Medicine, St. Louis, MO, USA.,

    Todd J Schwedt

Authors
  1. Todd J Schwedt
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schwedt, T. How long should patients with migraine continue to receive prophylactic topiramate?. Nat Rev Neurol 4, 294–295 (2008). https://doi.org/10.1038/ncpneuro0770

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneuro0770

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing